Polypharmacy and potential drug–drug interactions among people living with HIV in the era of integrase strand transfer inhibitor-based antiretroviral therapy
- 22 December 2023
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 63 (2) , 107067
Abstract
No abstract availableKeywords
Funding Information
- Gilead Sciences (110-158-E, 202109109RINB)
This publication has 17 references indexed in Scilit:
- Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016JAMA Network Open, 2020
- The effect of multivitamins and polyvalent cations on virologic suppression with integrase strand transfer inhibitorsAIDS, 2020
- The challenge of HIV treatment in an era of polypharmacyJournal of the International AIDS Society, 2020
- Polypharmacy and evaluation of anticholinergic risk in a cohort of elderly people living with HIVAIDS, 2019
- Prevalence and related drug cost of comorbidities in HIV-infected patients receiving highly active antiretroviral therapy in Taiwan: A cross-sectional studyJournal of Microbiology, Immunology and Infection, 2019
- Polypharmacy and Drug–Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based StudyClinical Infectious Diseases, 2019
- Estimated risk of cardiovascular disease among the HIV-positive patients aged 40 years or older in TaiwanJournal of Microbiology, Immunology and Infection, 2019
- Polypharmacy and Drug–drug Interactions in Older and Younger People Living with HIV: The POPPY StudyAntiviral Therapy, 2018
- Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General PopulationClinical Infectious Diseases, 2011
- The Anticholinergic Risk Scale and Anticholinergic Adverse Effects in Older PersonsArchives of internal medicine (1960), 2008